Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity
Chiara Fallerini(University of Siena), Sabino Scolletta(Université Libre de Bruxelles), Giada Beligni(University of Siena), Elisa Benetti(University of Siena), Chiara Gabbi(Karolinska Institutet), Paolo Cameli(University of Siena), Sergio Daga(University of Siena), Maria Palmieri(University of Siena), Marco Gori(University of Siena), Francesca Fava(University of Siena), Massimiliano Fabbiani(University of Siena), J. Kenneth Baillie(NHS Lothian), Laura Bergantini(University of Siena), Margherita Baldassarri(University of Siena), Mirjam Lista(University of Siena), Hugo Zeberg(Karolinska Institutet), Maddalena Fratelli(Mario Negri Institute for Pharmacological Research), Nicola Picchiotti(University of Siena), Michael Hultström(Uppsala University), Miklós Lipcsey(Uppsala University), Francesca Colombo(ACS Dobfar (Italy)), Kristina Zguro(University of Siena), Francesca Minnai(Institute of Biomedical Technologies), David Bennett(Rush University Medical Center), Sara Amitrano(Azienda Ospedaliera Universitaria Senese), Marco Tanfoni(University of Siena), Eva C. Schulte(Argonne National Laboratory), Elisa Frullanti(University of Siena), Stefania Mantovani(Policlinico San Matteo Fondazione), Ilaria Rancan(University of Siena), Brent Richards(McGill University), Francis P. Crawley(European Forum for Good Clinical Practice), Enrico Cabri(Mario Negri Institute for Pharmacological Research), Mirella Bruttini(University of Siena), Mario Tumbarello(University of Siena), Robert Frithiof(Uppsala University), Federico Anedda(University of Siena), Susanna Croci(University of Siena), Guillaume Butler‐Laporte(McGill University), Ilaria Meloni(University of Siena), Barbara Rossetti, Erola Pairo‐Castineira(Roslin Institute), Francesca Montagnani(University of Siena), Miriana d’Alessandro(Health & Life (Taiwan)), Simona Marcantonio(University of Siena), Floriana Valentino(University of Siena)
Cited by 41
Related Papers
An atlas of active enhancers across human cell types and tissues
|Nature|2014|2.8k
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k